A pending regulation under White House review could expand pharmacy compounding access to peptide products, which are widely marketed through wellness channels despite limited oversight. A panel of FDA outside advisers narrowly recommended adding several peptides to the agency’s list of products that can be compounded at pharmacies, while FDA scientists raised concerns. The American Academy of Peptide Medicine is scheduled to meet with the Office of Management and Budget to discuss the policy proposal. Alliance for Pharmacy Compounding CEO Scott Brunner said the notice could be “potentially significant,” adding that the community is waiting for details on covered peptides and possible conditions. The development matters for biotech-adjacent stakeholders because peptide therapeutics and peptide research reagents often sit at the boundary between drug regulation, compounding supply chains, and clinical use expectations. While not a drug-approval action, the direction could affect how quickly certain peptide products move through compounding channels, influencing availability for research and off-label use patterns.